Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0312603 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Nimer S Alkhatib und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Infliximab, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV) administration. However, the financial implications of this formulation have not been examined from the perspective of Saudi payers. Methods and materials A prevalence-based budget impact model was developed to evaluate the financial effects of introducing "environment without" versus "with infliximab SC." The model’s time horizon spanned over 2 years (2021–2023), aligning with the biennial national pharmaceutical procurement cycle. The comparison focused on infliximab SC versus all available formulations of infliximab IV in the Saudi market for two inflammatory bowel diseases (IBD): Ulcerative Colitis (UC) and Crohn’s Disease (CD). Treatment comparators’ comparability and dose escalations were substantiated by published studies, utilizing dosing information from the summary of product characteristics. Drug acquisition costs were derived from SFDA registered prices, with IV formulation administration costs included. Scenario analysis assessed the budget impact of infliximab SC introduction at uptake rates ranging from 0% to 100%.
Results
Introducing infliximab SC demonstrated cost-saving potential in the treatment of IBD. At 100% uptake with UC patients for 2 years, infliximab SC resulted in savings of -SAR-31.9 million (-SAR29,145 per patient). Similarly, for CD, introducing infliximab SC at 100% uptake over 2 years yielded savings of -SAR106.2 million (-SAR36,585 per patient).
Conclusion
This study reveals that infliximab SC is associated with cost-saving potential when compared to infliximab IV formulations available in Saudi Arabia. Future research should address uncertainties related to real-world comparative effectiveness, the convenience of administration, patient tolerability, and physician acceptance of the SC formulation of infliximab, alongside comparisons with other TNF-alpha inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
- Path Economics, LLC, Amman, Jordan.
- Drug Sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
- Gastroenterology Division, Department of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
- Division of Gastroenterology, The McGill University Health Center, Montreal General Hospital, McGill University, Montreal, Canada.
- Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.
ORCID-Profile: Nimer S Alkhatib, Yazed Sulaiman H Al-Ruthia, Amal M Badawoud, Majed S Al Yami
Zitieren
APA
Alkhatib, N. S., Almutairi, A. R., Almadi, M., Halloush, S., Al-Ruthia, Y. S. H., Rashdan, O., Al-Shatnawi, S., Azzam, N. A., Mosli, M. H., Badawoud, A. M., Al Yami, M. S., Alhossan, A., & AlHarbi, I. (2024). Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective. PLOS ONE. https://doi.org/10.1371/journal.pone.0312603
Vancouver
Alkhatib NS, Almutairi AR, Almadi M, Halloush S, Al-Ruthia YSH, Rashdan O, et al. Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective. PLOS ONE. 2024. doi:10.1371/journal.pone.0312603
BibTeX
@article{Alkhatib2024,
author = {Alkhatib, Nimer S and Almutairi, Abdulaali R and Almadi, Majid and Halloush, Shiraz and Al-Ruthia, Yazed Sulaiman H and Rashdan, Omar and Al-Shatnawi, Samah and Azzam, Nahla A and Mosli, Mahmoud H and Badawoud, Amal M and Al Yami, Majed S and Alhossan, Abdulaziz and AlHarbi, Ibtisam},
title = {Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0312603}
}
EUVIMED